CytoSorbents to Present at the 2016 BIO Investor Forum
MONMOUTH JUNCTION, N.J., Oct. 14, 2016 /PRNewswire/ — CytoSorbents Corporation CTSO, -2.63% a critical care immunotherapy leader commercializing its flagship CytoSorb® extracorporeal cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CEO Dr. Phillip Chan, MD, PhD, will present at the 2016 BIO Investor Forum taking place October 18-19, 2016 in San Francisco. A live webcast of the presentation will be available during and after the event.
Conference Presentation Details: Where: Westin St. Francis Hotel, 335 Powell St, San Francisco, CA 94102 When: Tuesday, October 18, 2016 at 4:30PM PDTRoom: Elizabethan A Webcast: https://www.veracast.com/webcasts/bio/investorforum2016/91130180661.cfm Conference Website: https://www.bio.org/events/bio-investor-forum
Currently, the company has limited availability to schedule one-on-one meetings with institutional investors. To schedule a meeting, please contact Lea Garcia at email@example.com.
About CytoSorbents Corporation (NASDAQ: CTSO )
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In early 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 14,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites: http://www.cytosorbents.com and http://www.cytosorb.com or follow us on Facebook and Twitter.
About BIO and the BIO Investor Forum
BIO, the Biotechnology Innovation Organization, is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
The BIO Investor Forum is an international biotechnology investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-one Partnering™ meetings.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Cytosorbents Contact:Amy Vogel
(732) 329-8885 ext. *825
Public Relations Contact:
Amy Phillips Pascale Communications 412-327-9499 firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-2016-bio-investor-forum-300344941.html
SOURCE CytoSorbents Corporation
Copyright (C) 2016 PR Newswire. All rights reserved